last
decad
centuri
diagnost
advanc
dramat
reduc
transmiss
human
immunodefici
viru
hiv
hepat
c
viru
hcv
hepat
b
viru
hbv
transfus
howev
simultan
emerg
addit
pathogen
potenti
blood
contamin
gain
attent
agent
repres
newli
discov
entiti
eg
sever
acut
respiratori
syndrom
sarscoa
other
known
sourc
transfus
complic
expand
unit
state
eg
chaga
diseas
addit
agent
demonstr
speci
jump
anim
host
human
eg
variant
creutzfeldtjakob
diseas
vcjd
asian
influenza
west
nile
viru
increas
global
commerc
travel
social
interact
requir
mani
infecti
agent
thought
exot
remot
signific
must
consid
potenti
bloodcompon
contamin
altern
new
inform
may
reduc
concern
exampl
porcin
endogen
retroviru
perv
previous
link
human
undergo
xenotransplant
current
appear
less
threaten
chapter
address
agent
endem
unit
state
emerg
part
world
transmit
theoret
capabl
transmiss
transfus
approach
reduc
associ
risk
babesiosi
zoonosi
caus
rodentborn
piroplasm
protozoan
babesia
microti
transmit
ixod
scapulari
deer
blackleg
tick
scapulari
also
transmit
agent
lyme
diseas
human
granulocyt
ehrlichiosi
discuss
later
whitefoot
mous
peromyscu
leucopu
natur
reservoir
b
microti
infect
mous
remain
parasitem
indefinit
scapulari
transmit
piroplasm
frequent
nymphal
stage
tick
mm
long
tick
bite
stage
often
go
unnot
despit
feed
time
infect
occur
b
microti
agent
frequent
associ
clinic
ill
also
caus
clinic
diseas
endem
area
includ
coastal
island
area
new
england
new
york
well
part
california
washington
missouri
wisconsin
minnesota
tick
coinfect
b
microti
borrelia
burgdorferi
agent
lyme
diseas
transmit
b
microti
less
frequent
b
burgdorferi
tick
less
compet
host
b
microti
intraerythrocyt
local
b
microti
howev
favor
transfus
transmiss
agent
b
burgdorferi
human
circul
b
microti
dna
persist
averag
day
asymptomat
patient
given
specif
treatment
coinfect
lyme
diseas
alter
durat
parasitemia
parasit
circul
day
person
treat
clindamycin
quinin
altern
antibiot
regimen
includ
atovaquon
azithromycin
silent
babesia
infect
occur
commonli
infect
individu
develop
chronic
carrier
state
lase
month
year
other
recrudesc
occur
spontan
splenectomi
immunosuppress
parasit
retain
infect
red
blood
cell
rbc
compon
refriger
frozen
temperatur
residu
rbc
contain
platelet
concentr
store
room
temperatur
date
posttransfus
case
involv
b
microti
babesia
speci
report
sever
report
involv
donor
transmit
infect
multipl
donat
given
month
apart
overal
risk
acquir
transfusionassoci
babesiosi
low
vari
region
connecticut
seroneg
donor
becam
seroposit
subsequ
donat
anoth
studi
donor
endem
nonendem
area
connecticut
confirmatori
indirect
immunofluoresc
assay
ifa
posit
test
result
babesia
infect
preval
rate
peak
juli
donor
seroposit
repres
rel
high
potenti
threat
endem
area
recipi
becam
seroposit
receiv
blood
ifaposit
blood
donor
asplenia
older
age
immunodefici
organ
transplant
liver
diseas
increas
risk
sever
babesia
ill
acut
symptomat
case
fatigu
malais
weak
fever
occur
patient
shake
chill
diaphoresi
nausea
anorexia
headach
myalgia
occur
frequent
heart
murmur
hepatomegali
splenomegali
found
patient
jaundic
occur
less
frequent
renal
failur
dissemin
intravascular
coagul
adult
respiratori
distress
syndrom
report
averag
hemoglobin
concentr
gdl
review
hospit
patient
communityacquir
babesiosi
examin
blood
smear
intraerythrocyt
ring
form
maltes
crosslik
tetrad
includ
two
parasit
per
cell
contort
shape
vacuol
bud
antibabesi
antibodi
assay
polymeras
chain
reaction
pcr
assay
babesi
dna
provid
laboratori
evid
infect
transfusionassoci
babesia
case
involv
rbc
transfus
although
frozendeglycerol
rbc
platelet
unit
implement
transfusionacquir
case
incub
period
week
bloodcollect
agenc
ask
prospect
donor
whether
ever
babesiosi
answer
affirm
defer
howev
donor
ask
recent
histori
tick
bite
geograph
resid
low
predict
valu
associ
question
exampl
donor
connecticut
report
tick
bite
seroposit
babesiosi
antibodi
compar
report
tick
bite
serolog
pcr
test
impract
time
absenc
specif
intervent
interdict
donor
capabl
transmit
babesia
infect
releg
clinic
awar
prompt
antibiot
therapi
primari
modal
treat
infrequ
complic
transfus
therapi
borrelia
burgdorferi
spirochet
caus
lyme
diseas
tickborn
zoonosi
present
mice
squirrel
small
anim
human
lyme
diseas
case
occur
annual
unit
state
although
none
associ
transfus
endem
area
includ
northeastern
midatlant
upper
northcentr
region
unit
state
ixod
scapulari
black
leg
deer
tick
transmit
b
burgdorferi
northeastern
northcentr
part
unit
state
pacificu
western
blackleg
tick
transmit
infect
along
pacif
coast
tick
feed
predominantli
late
spring
earli
summer
nymphal
stage
lyme
diseas
usual
result
bite
infect
nymph
deer
becom
infect
rather
transport
maintain
tick
patient
lyme
diseas
typic
present
characterist
erythema
migran
rash
accompani
fever
malais
headach
myalgia
arthralgia
bell
palsi
rash
occur
day
tick
bite
b
burgdorferi
spirochet
dissemin
entri
site
via
cutan
lymphat
bloodborn
rout
one
studi
spirochet
isol
blood
patient
symptomat
lyme
diseas
b
burgdorferi
also
isol
erythema
migran
lesion
diagnosi
lyme
diseas
base
primarili
characterist
symptom
physic
examin
find
histori
possibl
tick
exposur
serolog
test
includ
enzymelink
immunoassay
ifa
test
becom
posit
week
infect
western
blot
test
use
confirm
result
reactiv
screen
test
treatment
antibiot
clear
infect
addit
treatment
reliev
symptom
prescrib
arthriti
persist
two
antibiot
cours
postlym
diseas
syndrom
despit
document
spirochet
surviv
routin
rbc
frozen
plasma
storag
test
blood
donor
consider
report
exist
transfusionassoci
lyme
diseas
note
transfus
rbc
platelet
collect
peak
deer
tick
activ
patient
undergo
cardiothorac
surgeri
result
serolog
clinic
evid
lyme
diseas
individu
histori
lyme
diseas
accept
blood
donor
provid
treat
asymptomat
month
last
dose
antibiot
rickettsi
agent
human
monocyt
ehrlichiosi
hme
human
granulocyt
ehrlichiosi
hge
intracellular
organ
surviv
store
blood
caus
mild
sever
ill
ehrlichia
chaffeensi
caus
hme
transmit
human
bite
lone
star
tick
amblyomma
americanum
previous
infect
contact
deer
possibl
dog
report
case
occur
southcentr
southeastern
unit
state
anaplasma
phagocytophila
caus
hge
relat
close
speci
infect
hors
ehrlichia
equi
rumin
ehrlichia
phagocytophila
ill
occur
predominantli
northeastern
upper
midwestern
northwestern
area
unit
state
transmit
human
scapulari
pacificu
tick
fifti
percent
tick
examin
one
studi
connecticut
infect
hge
agent
none
infect
e
chaffeensi
patient
hme
hge
present
similarli
fever
headach
myalgia
thrombocytopenia
leukopenia
elev
liver
enzym
concentr
rash
occur
one
third
patient
hme
fewer
patient
hge
membranebound
intracytoplasm
ehrlichia
aggreg
morula
present
monocyt
complic
includ
respiratori
distress
renal
failur
neurolog
disord
dissemin
intravascular
coagul
septicemia
vascul
thrombot
thrombocytopen
purpura
consid
differenti
diagnosi
doxycyclin
treatment
choic
ehrlichia
present
blood
transfus
transmiss
must
consid
one
case
transfusionassoci
hge
occur
day
rbc
transfus
donat
asymptomat
donor
expos
extens
deer
tick
month
previous
infect
rbc
store
day
transfus
vitro
studi
suggest
leukocyt
reduct
may
complet
effect
prevent
e
chaffeensi
transmiss
pathogen
found
cell
free
plasma
fraction
extens
epidemiolog
studi
arkansa
involv
militari
traine
blood
donor
expos
tick
bite
unknowingli
infect
agent
ehrlichiosi
rocki
mountain
spot
fever
rmsf
found
clinic
ill
among
recipi
rbc
platelet
donat
soldier
howev
possibl
seroconvers
rmsf
occur
one
recipi
singl
case
report
publish
clinic
ill
associ
transfusiontransmit
rmsf
infect
donor
develop
symptom
rmsf
day
donat
die
day
later
recipi
develop
fever
headach
day
receiv
implic
rickettsia
rickettsiiinfect
transfus
notifi
donor
ill
treat
effect
tickborn
agent
implic
transfusionassoci
case
includ
colorado
tick
fever
viru
tickborn
enceph
viru
although
risk
transfus
transmiss
agent
low
clinic
suspicion
import
mechan
determin
infect
organ
malaria
protozoan
diseas
caus
four
speci
genu
plasmodium
p
falciparum
p
vivax
p
oval
p
malaria
tabl
protozoa
transmit
human
bite
infect
femal
mosquito
genu
anophel
infect
human
host
absent
treatment
result
chronic
intraerythrocyt
infect
transmit
blood
transfus
twohost
life
cycl
malaria
parasit
diagram
figur
although
sign
symptom
malaria
variabl
patient
febril
mani
also
manifest
headach
chill
sweat
nausea
vomit
diarrhea
back
pain
myalgia
cough
diagnosi
malaria
consid
patient
symptom
histori
travel
malariaendem
area
recent
blood
transfus
given
period
report
local
mosquitoborn
transmiss
malaria
also
consid
differenti
diagnosi
patient
fever
unknown
origin
regardless
travel
histori
malaria
diagnos
microscop
find
intraerythrocyt
parasit
giemsastain
peripher
blood
smear
properli
prepar
thick
thin
smear
must
examin
train
laboratori
personnel
make
accur
laboratori
diagnosi
patient
neg
smear
suspect
malaria
addit
smear
examin
daili
day
pcr
use
adjunct
case
serial
test
smear
yield
neg
result
malaria
huge
global
public
health
problem
estim
annual
incid
million
case
million
death
per
year
malariaendem
area
includ
part
africa
asia
central
america
hispaniola
north
america
oceania
south
america
earli
part
centuri
specif
estim
case
malaria
occur
continent
unit
state
sinc
improv
socioeconom
condit
water
manag
vector
control
case
manag
prevent
endem
malaria
transmiss
ongo
malaria
surveil
unit
state
center
diseas
control
prevent
cdc
continu
identifi
case
immigr
resid
travel
area
world
malaria
transmiss
still
occur
addit
year
case
report
might
repres
local
mosquitoborn
transmiss
exampl
seven
case
local
acquir
mosquitotransmit
p
vivax
malaria
report
palm
beach
counti
florida
multilocu
genotyp
ribosom
rna
isol
seven
patient
reveal
infect
strain
congenit
infect
transfusionacquir
infect
round
sourc
malaria
case
diagnos
year
unit
state
case
malaria
unit
state
onset
symptom
one
due
transmiss
p
malaria
blood
transfus
case
report
one
due
transmiss
p
falciparum
blood
transfus
overwhelm
major
report
case
year
import
ie
acquir
outsid
unit
state
data
show
case
frequent
identifi
foreign
civilian
us
civilian
howev
sinc
situat
revers
case
unit
state
civilian
report
time
number
foreign
civilian
like
due
increas
travel
us
civilian
endem
area
decreas
immigr
sinc
case
among
us
civilian
travel
occur
person
fail
take
prophylact
drug
taken
cdcrecommend
drug
noncompli
recommend
drug
mosquito
genu
anophel
except
feed
dusk
dawn
except
daytim
feed
dens
shade
woodland
dark
interior
hous
shelter
therefor
travel
visit
malari
area
bright
daylight
hour
littl
risk
acquir
malaria
return
nonmalari
area
dusk
transfusiontransmit
malaria
occur
estim
rate
case
per
million
blood
unit
collect
low
incid
lack
laboratori
test
approv
us
food
drug
administr
fda
prevent
transfusiontransmit
malaria
continu
depend
sole
donordeferr
guidelin
establish
fda
recent
updat
current
prospect
donor
resid
countri
malaria
endem
travel
malariaendem
area
temporarili
defer
year
departur
endem
area
remain
free
symptom
suggest
malaria
immigr
refuge
citizen
resid
malariaendem
area
defer
year
persist
liver
caus
relaps
invad
bloodstream
week
even
year
later
initi
replic
liver
exoerythrocyt
schizogoni
parasit
undergo
asexu
multipl
erythrocyt
erythrocyt
schizogoni
merozoit
infect
red
blood
cell
ringstag
trophozoit
matur
schizont
ruptur
releas
merozoit
parasit
differenti
sexual
erythrocyt
stage
gametocyt
bloodstag
parasit
respons
clinic
manifest
diseas
gametocyt
male
microgametocyt
femal
macrogametocyt
ingest
anophel
mosquito
blood
meal
parasit
multipl
mosquito
known
sporogon
cycl
mosquito
stomach
microgamet
penetr
macrogamet
gener
zygot
zygot
turn
becom
motil
elong
ookinet
invad
midgut
wall
mosquito
develop
oocyst
oocyst
grow
ruptur
releas
sporozoit
make
way
mosquito
salivari
gland
inocul
sporozoit
new
human
host
perpetu
malaria
life
cycl
departur
endem
area
remain
free
symptom
suggest
malaria
prospect
donor
diagnos
treat
malaria
defer
year
becom
asymptomat
three
case
posttransfus
malaria
due
p
falciparum
two
fatal
diagnos
unit
state
prompt
review
cdc
case
transfusiontransmit
malaria
report
see
tabl
updat
includ
report
case
total
case
per
year
report
thirtyfour
case
caus
p
falciparum
p
vivax
p
malaria
p
oval
mix
speci
undetermin
speci
p
falciparum
case
increas
frequenc
period
account
case
interv
compar
case
report
fatal
case
overal
associ
p
falciparum
p
vivax
p
malaria
incub
period
case
rang
day
p
falciparum
shortest
time
mean
day
rang
day
p
malaria
longest
mean
day
rang
day
period
onset
symptom
time
diagnosi
rang
day
median
day
ninetyfour
percent
case
associ
transfus
whole
blood
rbc
plateletassoci
implic
donor
defin
met
one
follow
criteria
blood
smear
demonstr
malaria
parasit
posit
result
malaria
serolog
donor
ninetythre
donor
implic
case
median
number
donor
per
case
seven
rang
donor
overwhelmingli
male
rang
age
year
median
year
foreignborn
donor
account
africa
born
unit
state
donor
implic
case
epidemiolog
followup
complet
serolog
effect
tool
identifi
transmit
donor
identifi
posit
blood
smear
serolog
blood
smear
posit
implic
donor
case
analysi
case
use
current
donor
deferr
guidelin
reveal
case
occur
despit
proper
applic
guidelin
review
guidelin
place
time
occur
case
could
evalu
date
onset
guidelin
vagu
remain
case
would
still
occur
would
prevent
thencurr
guidelin
appli
properli
surprisingli
case
occur
despit
follow
guidelin
caus
p
malaria
continu
occurr
case
face
current
histori
question
highlight
realiti
malaria
risk
transfus
although
low
fulli
prevent
question
donor
although
deferr
guidelin
current
place
base
biolog
four
speci
plasmodia
caus
malaria
repres
balanc
struck
maxim
safeti
minim
donor
loss
p
vivax
p
oval
speci
give
rise
relaps
infect
rare
persist
longer
year
howev
infect
persist
individu
prolong
infect
transmit
malaria
blood
transfus
likewis
diseas
caus
p
falciparum
nonrelaps
speci
manifest
within
year
departur
malari
area
time
report
falciparum
malaria
occur
year
departur
malari
area
publish
wellknown
abil
p
malaria
persist
asymptomat
decad
individu
highlight
difficulti
erad
risk
posttransfus
malaria
question
donor
aabb
advoc
use
uniform
donor
screen
question
elicit
malaria
risk
prospect
donor
includ
question
inquir
histori
malaria
prospect
donor
travel
histori
within
past
year
ye
answer
travel
outsid
unit
state
canada
trigger
inquiri
pinpoint
travel
destin
malari
area
fda
process
revis
guidelin
deferr
blood
donor
risk
malaria
howev
unclear
agenc
issu
new
guidelin
propos
guidelin
discuss
fda
blood
product
advisori
committe
meet
june
addit
retain
provis
donor
deferr
outlin
fda
memo
juli
revis
guidelin
recommend
ad
follow
question
sequenc
donor
histori
form
born
unit
state
ye
ask
past
year
outsid
unit
state
canada
answer
ask
arriv
unit
state
sinc
arriv
travel
outsid
unit
state
canada
answer
question
second
question
ye
followup
question
ask
donor
determin
countri
countri
visit
impetu
revis
guidelin
includ
increas
number
import
malaria
case
unit
state
larg
number
postdon
event
relat
malaria
report
fda
recognit
elicit
accur
donor
histori
current
avail
defens
transfusiontransmit
malaria
time
time
propos
test
donor
evid
malaria
advanc
fdaapprov
test
polici
screen
donor
current
place
select
screen
highrisk
donor
suggest
altern
univers
screen
bloodsmear
diagnosi
impract
insensit
donorscreen
techniqu
ifa
test
use
diagnost
unsuit
largescal
donor
screen
although
could
use
test
highrisk
donor
determin
suitabl
although
antibodi
assay
detect
individu
parasitemia
also
posit
treat
person
longer
parasitem
henc
noninfecti
donor
would
also
defer
select
antibodi
screen
implement
pcr
promis
approach
may
requir
sensit
specif
current
standard
avail
outsid
research
laboratori
american
trypanosomiasi
chaga
diseas
zoonosi
caus
hemoflagel
protozoan
parasit
trypanosoma
cruzi
life
cycl
cruzi
involv
transmiss
insect
vector
mammalian
host
includ
human
cruzi
infect
human
triatomid
reduviid
kiss
bug
ingest
blood
meal
host
deposit
infect
fece
wound
contamin
fece
contact
mucos
surfac
eye
mouth
hematogen
spread
occur
subsequ
addit
cruzi
cross
placenta
caus
congenit
diseas
fig
acut
chaga
diseas
associ
fever
facial
edema
gener
lymphadenopathi
hepatosplenomegali
symptomat
myocard
meningioenceph
occur
fulmin
ill
develop
immunolog
immatur
children
immunocompromis
adult
howev
patient
ill
mild
symptom
resolv
week
untreat
host
enter
indetermin
phase
ten
percent
patient
progress
indetermin
asymptomat
phase
chronic
symptomat
phase
associ
cardiac
enlarg
apic
aneurysm
mural
thrombi
megaesophagu
megacolon
appear
year
decad
infect
epidemiolog
estim
million
peopl
infect
south
america
central
america
mexico
chaga
diseas
endem
histor
triatomid
insect
resid
crack
rural
suburban
hous
adob
wall
unit
state
estim
person
blood
donor
may
infect
cruzi
almost
immigr
central
south
america
chaga
diseas
respons
death
worldwid
annual
lifelong
lowgrad
parasitemia
persist
approxim
infect
seroposit
blood
donor
parasitemia
present
risk
transfus
transmiss
vertic
transmiss
infant
recipi
parasitem
blood
becom
infect
estim
risk
transfusionassoci
chaga
diseas
relat
immigr
pattern
endem
region
nicaraguan
salvadorian
immigr
live
washington
dc
serolog
evid
cruzi
infect
parasit
isol
half
earli
select
blooddonor
popul
california
us
southwest
seroposit
cruzi
antibodi
least
donor
hispan
origin
donor
hospit
lo
angel
respond
affirm
question
inquir
birth
chaga
diseaseendem
area
resid
dwell
construct
palm
leafthatch
roof
wall
made
mud
test
posit
cruzi
antibodi
studi
conduct
midtol
involv
million
blood
donor
lo
angel
miami
cruzi
seroposit
although
correl
exist
percentag
immigr
endem
area
percentag
blood
donor
serolog
evid
cruzi
infect
investig
also
identifi
seroposit
blood
donor
born
unit
state
congenit
transmiss
may
explain
infect
individu
addit
autochthon
transmiss
report
unit
state
infest
triatomin
report
texa
sinc
seven
case
transfusionassoci
chaga
diseas
occur
unit
state
canada
symptom
develop
approxim
month
transfus
least
six
case
platelet
implic
blood
compon
howev
seventh
case
implic
unit
identifi
centrifug
may
sediment
cruzi
platelet
layer
compon
prepar
account
associ
platelet
transfus
wherea
roomtemperatur
storag
platelet
may
favor
parasit
surviv
cruzi
shown
surviv
refriger
rbc
whole
blood
least
day
six
north
american
transfusionassoci
case
donor
emigr
cruziendem
region
bolivia
mexico
paraguay
chile
identifi
four
donor
emigr
year
implic
donat
given
small
number
case
transfus
transmiss
chaga
diseas
may
ineffici
studi
patient
receiv
blood
blood
donor
subsequ
found
cruzi
seroposit
none
recipi
becam
seroposit
transfus
howev
two
receiv
platelet
transfus
report
chaga
diseas
also
report
transplant
involv
organ
donor
emigr
central
america
appear
recipi
kidney
pancrea
die
acut
chaga
myocard
month
transplant
recipi
kidney
liver
also
infect
cruzi
intervent
reduc
risk
transfusiontransmit
chaga
diseas
includ
question
donor
geograph
locat
birth
extend
stay
transfus
area
endem
chaga
diseas
serolog
test
donor
histori
question
may
effect
least
one
candid
serolog
screen
assay
undergon
clinic
trial
unit
state
current
review
fda
us
fda
indic
requir
test
chaga
diseas
appropri
screen
assay
achiev
licensur
decis
reflect
report
transfusionand
organ
transplantassoci
case
concern
transmiss
may
occur
annual
unit
state
leukocyt
reduct
filtrat
modestli
effect
reduc
cruzii
transmiss
mous
transfus
model
serolog
test
blood
donat
syphili
institut
requir
regul
case
transfusionassoci
syphili
occur
unit
state
sinc
multipl
factorsimprov
donor
select
uniform
serolog
test
lack
spirochet
viabil
blood
store
refriger
temperatur
widespread
antibiot
useappar
contribut
current
absenc
transfusiontransmit
syphili
case
aabb
standard
committe
delet
requir
syphili
test
fda
advisori
panel
propos
elimin
requir
serolog
syphili
test
howev
chang
made
belief
test
might
identifi
risk
transmit
hiv
subsequ
observ
data
support
assumpt
nonetheless
nation
institut
health
consensu
statement
issu
januari
recommend
continu
syphili
test
role
prevent
transfusiontransmit
syphili
understood
lack
complet
laboratori
data
also
support
test
retent
although
spirochet
surviv
hour
refriger
temperatur
viabil
room
temperatur
eg
platelet
concentr
studi
furthermor
loss
viabil
storag
incomplet
protect
mechan
singl
optim
laboratori
test
exist
syphili
infecti
agent
treponema
pallidum
anaerob
organ
cultur
vitro
treponema
infect
nontreponem
treponem
antibodi
produc
nontreponem
antibodi
reagin
antibodi
react
phospholipid
isol
beef
heart
cardiolipin
antibodi
detect
vener
diseas
research
laboratori
vdrl
rapid
plasma
reagin
rpr
test
respons
interact
infect
host
tissu
pallidum
parallel
patholog
cours
relat
immun
treponemaspecif
antibodi
higher
serolog
sensit
earli
stage
syphili
less
effect
indic
diseas
activ
first
week
primari
infect
vdrl
posit
case
fluoresc
treponem
antibodyabsorpt
ftaab
test
posit
treponem
antibodi
test
often
use
confirm
nontreponem
test
includ
pallidum
particl
aggreg
tppa
recombin
antigen
test
autom
test
treponem
antibodi
pk
tm
treponema
pallidum
pktp
perform
olympu
pk
wide
use
reaction
pattern
character
posit
rpr
pktp
test
neg
ftaab
reaction
socal
falseposit
reaction
may
caus
hepat
mononucleosi
viral
pneumonia
chickenpox
measl
immun
pregnanc
laboratori
error
persist
falseposit
reaction
report
patient
rheumatoid
arthriti
cirrhosi
ulcer
coliti
vascul
older
age
among
pktpand
ftaabsposit
blood
donor
approxim
half
give
prior
histori
treat
syphili
infect
histori
lupu
rheumatoid
arthriti
diabet
provid
explan
nonconfirm
pktp
result
typic
first
sign
syphili
chancr
appear
day
averag
day
exposur
exact
time
spirochetemia
pallidum
dissemin
chancr
seroconvers
known
secondari
syphili
character
dissemin
rash
spirochetemia
occur
week
infect
serolog
test
almost
univers
posit
patient
remain
untreat
recurr
fulmin
secondari
syphili
recur
within
year
approxim
subsequ
patient
becom
immun
reinfect
becom
noninfecti
vdrl
titer
decreas
time
unless
patient
treat
primari
stage
treponem
antibodi
persist
treat
untreat
patient
tertiari
syphili
develop
variabl
length
time
reactiv
clinic
serolog
notic
via
anticardiolipin
treponem
antibodi
detect
current
donat
reactiv
syphili
screen
test
unsuit
unless
nonreact
confirmatori
test
confirmatori
test
posit
donor
defer
year
allow
donat
provid
undergon
adequ
treatment
syphili
nontreponem
assay
neg
human
parvoviru
discov
serendipit
human
plasma
blooddonor
screen
hepat
b
surfac
antigen
initi
parvoviru
link
causal
transient
aplast
crise
patient
sickl
cell
anemia
subsequ
patient
inherit
hemolyt
diseas
result
sever
reticulocytopenia
anemia
later
found
etiolog
agent
fifth
diseas
erythema
infectiosum
common
childhood
ill
manifest
erythemat
rash
rash
occur
less
often
infect
adult
children
fever
nonspecif
symptom
preced
rash
arthralgia
probabl
result
immun
complex
deposit
skin
organ
hepat
myocard
vascul
glovesandsock
syndrom
also
link
infect
fig
infect
human
transmiss
occur
commonli
via
respiratori
rout
addit
transplacent
transmiss
parvoviru
occur
women
infect
pregnanc
women
infect
week
pregnanc
hydrop
fetali
fetal
death
occur
approxim
viru
highli
tropic
erythroid
progenitor
cell
gain
access
cell
blood
group
p
antigen
globosid
identifi
viru
receptor
viral
genom
consist
singlestrand
dna
code
three
protein
nonstructur
protein
cytopath
host
cell
viral
protein
viral
protein
code
loop
appear
capsid
surfac
neutral
antibodi
recogn
nonenvelop
viru
consist
symmetr
particl
mm
diamet
infect
ubiquit
human
popul
alreadi
preval
pediatr
age
group
seropreval
studi
show
antibodi
frequenc
high
schoolag
children
older
adult
epidem
sporad
infect
may
occur
time
year
major
outbreak
erythema
infectiosum
occur
everi
year
persist
parvoviru
infect
includ
pure
rbc
aplasia
occur
develop
neutral
antibodi
viru
circul
high
titer
greater
genom
copi
per
millilit
patient
receiv
cytotox
chemotherapi
immunosuppress
drug
organ
transplant
recipi
patient
immunodefici
acquir
immunodefici
syndrom
aid
higher
risk
develop
chronic
infect
therapeut
approach
persist
parvoviru
infect
involv
discontinu
immunosuppress
therapi
administ
intraven
immunoglobulin
ivig
prepar
institut
antivir
therapi
aid
patient
give
repeat
cours
ivig
need
transient
hightit
viremia
accompani
acut
asymptomat
infect
allow
viru
transmiss
blood
blood
deriv
organ
transplant
infrequ
recognit
transfusionassoci
case
reflect
short
virem
phase
high
frequenc
immun
among
transfus
recipi
contrast
recipi
blood
transfus
almost
recipi
plasmaderiv
factor
viii
ix
concentr
risk
parvoviru
circul
blood
approxim
plasma
donor
fourteen
percent
titer
genom
equival
per
millilit
greater
genom
equival
per
millilit
surprisingli
plasma
deriv
prepar
largescal
plasma
pool
pcr
test
detect
parvoviru
lot
observ
studi
recipi
solventdetergenttr
plasma
seroconvert
infus
product
hightit
parvoviru
dna
genom
copi
per
millilit
suggest
presenc
antibodi
protect
larg
viral
load
seroconvers
occur
among
recipi
lot
viral
titer
genom
copi
per
millilit
viru
resist
viralinactiv
step
solventdeterg
treatment
heat
lyophil
vapor
stage
heat
may
reduc
infect
appli
liquid
state
children
receiv
plasmaderiv
factor
viii
concentr
least
like
seroposit
receiv
product
recombinantderiv
antihemophil
factor
parvoviru
seemingli
becom
concentr
plasma
fraction
use
factor
viii
prepar
despit
high
frequenc
parvoviru
exposur
longterm
sequela
appear
subtl
exampl
parvoviru
hemophil
children
loss
joint
rang
motion
differ
compar
seroneg
children
unlik
factor
viii
ix
albumin
transmit
parvoviru
one
report
implic
parvoviru
transmiss
ivig
base
detect
viral
dna
pcr
howev
document
show
viral
genotyp
recipi
immunoglobulin
prepar
light
data
regulatori
agenc
manufactur
plasma
deriv
sought
reduc
dna
level
genom
copi
per
millilit
plasma
pool
contain
plasma
donat
howev
subsequ
report
show
parvoviru
transmiss
occur
recipi
solventdetergenttr
antihemophil
factor
contain
genom
equival
per
millilit
recipi
dryheattr
factor
viii
product
contain
genom
equival
per
millilit
case
smaller
plasma
batch
high
viral
load
combin
form
larger
pool
use
manufactur
antihemophil
factor
concentr
current
manufactur
conduct
inprocess
test
elimin
plasma
donor
hightit
level
exampl
recov
plasma
plasma
obtain
wholeblood
donat
intend
fraction
plasma
deriv
undergo
dna
test
via
nucleic
acid
amplif
test
nat
assay
aliquot
pool
sampl
subpool
analys
perform
determin
sampl
contain
hightit
donor
hightit
unit
approxim
per
donat
withheld
product
manufactur
infect
transient
carrier
state
exist
infect
donor
identifi
specif
perman
defer
wholeblood
donat
rare
transmit
parvoviru
infect
test
singl
unit
rbc
platelet
plasma
parvoviru
consider
unit
state
transmiss
spongiform
encephalopathi
tse
occur
human
includ
kuru
cjd
diseas
phenotyp
variant
cjd
fatal
famili
insomnia
variant
cjd
vcjd
tse
occur
anim
includ
scrapi
sheep
goat
wast
diseas
deer
elk
transmiss
mink
encephalopathi
bovin
spongiform
encephalopathi
tse
infecti
agent
classifi
prion
proteinac
infecti
particl
lack
nucleic
acid
tse
resist
inactiv
agent
alcohol
formalin
ioniz
ultraviolet
irradi
proteas
nucleas
disrupt
autoclav
phenol
deterg
extrem
ph
affect
protein
normal
host
membran
prion
protein
prp
design
prp
c
whose
function
unknown
proteas
sensit
solubl
high
content
prion
diseas
appear
involv
conform
modif
prp
c
proteaseresist
alter
isoform
form
amyloid
fibril
design
prp
sc
convers
prp
c
prp
sc
result
refold
portion
coil
structur
prp
c
neuron
loss
vacuol
lead
spongioform
appear
brain
cortex
deep
nuclei
cjd
occur
incid
case
per
million
popul
worldwid
rate
increas
slightli
past
decad
presum
basi
improv
diagnost
accuraci
greater
number
older
individu
fewer
case
per
year
report
unit
state
sporad
cjd
caus
approxim
cjd
case
occur
person
year
age
averag
age
onset
year
manifest
disord
sleep
decreas
appetit
behavior
cognit
chang
focal
sign
visual
loss
cerebellar
ataxia
asplasia
motor
deficit
mean
surviv
time
month
mode
infect
sporad
cjd
uncertain
approxim
cjd
case
occur
patient
famili
histori
cjd
suggest
autosom
domin
inherit
pattern
mutat
prmp
gene
code
prion
protein
mutat
gene
locat
short
arm
chromosom
identifi
point
mutat
codon
occur
famili
case
approxim
cjd
case
involv
iatrogen
transmiss
exampl
cjd
transmit
corneal
transplant
patient
undiagnos
cjd
wherea
stereotact
electroencephalograph
silver
electrod
previous
implant
patient
cjd
subsequ
result
two
iatrogen
cjd
case
young
adult
die
year
receiv
intramuscular
human
growth
hormon
inject
prepar
cadaver
pituitari
gland
donor
unsuspect
cjd
cadaver
dura
mater
graft
commerci
product
prepar
batch
process
result
least
cjd
case
worldwid
occur
year
graft
placement
sporad
iatrogen
case
cjd
polymorph
involv
codon
prp
gene
appear
affect
suscept
normal
popul
methioninemethionin
homozyg
valinevalin
homozyg
codon
remain
heterozyg
homozyg
individu
repres
almost
sporad
iatrogen
cjd
case
homozyg
methionin
risk
fatal
famili
insomnia
wherea
homozyg
valin
risk
clinic
cjd
experi
involv
mice
infect
strain
diseas
bloodcompon
infect
demonstr
contrast
evid
transfusionassoci
cjd
document
casecontrol
studi
involv
patient
cjd
recipi
blood
person
subsequ
develop
cjd
examin
brain
tissu
deceas
hemophilia
patient
show
evid
cjd
transfusionassoci
cjd
case
report
date
nonetheless
occurr
iatrogen
case
theoret
risk
cjd
transmiss
blood
led
fda
issu
recommend
defer
donor
one
blood
rel
cjd
receiv
human
pituitaryderiv
growth
hormon
inject
dura
mater
transplant
indat
product
donor
risk
factor
must
quarantin
destroy
previou
recipi
blood
implic
donor
except
one
famili
member
cjd
must
notifi
spring
sever
dairi
cow
unit
kingdom
display
aggress
behavior
ataxia
fall
mad
cow
found
spongiform
lesion
brain
tissu
resembl
scrapi
subsequ
term
bovin
spongiform
encephalopathi
bse
cattl
succumb
bse
almost
million
may
infect
mean
incub
period
bse
year
cow
slaughter
year
age
cattl
manifest
diseas
approxim
bseinfect
cattl
enter
food
chain
first
bse
case
recogn
subsequ
onset
bse
epidem
trace
meatandbon
cattl
feed
made
sheep
cattl
pig
offal
render
process
presum
result
feed
scrapieinfect
materi
cow
use
sheep
offal
tissu
rumin
anim
feed
rumin
anim
ban
annual
incid
clinic
case
cattl
peak
march
anim
younger
month
elig
food
prepar
surveil
human
cjd
case
heighten
unit
kingdom
recognit
bse
epidem
ten
cjd
patient
unusu
neuropatholog
chang
predominantli
psychiatr
sensori
symptom
ataxia
dementia
myoclonu
younger
year
distinctli
unusu
characterist
cjd
electroencephalograph
featur
typic
cjd
florid
prp
plaqu
seen
neuropatholog
examin
median
surviv
time
month
contrast
month
cjd
case
consid
new
variant
cjd
vcjd
median
incub
period
foodborn
vcjd
year
extens
investig
use
anim
model
provid
evid
prion
strain
caus
bse
vcjd
ingest
british
beef
therefor
identifi
risk
factor
bse
june
case
vcjd
report
unit
kingdom
franc
ireland
portug
spain
itali
netherland
saudi
arabia
japan
canada
unit
state
latter
three
plu
one
irish
patient
thought
result
exposur
unit
kingdom
japanes
patient
spent
day
unit
kingdom
patient
test
homozyg
methionin
prp
codon
incid
human
vcjd
case
peak
suggest
clinic
manifest
among
methioninemethionin
homozygot
may
less
anticip
extens
exposur
cattl
subclin
diseas
concern
transfus
transmiss
vcjd
increas
prp
sc
found
consist
lymphoreticular
system
vcjd
patient
possibl
circul
prion
transfer
infect
gut
brain
eventu
anim
studi
anim
model
experi
sheep
fed
aliquot
brain
obtain
bseinfect
cattl
subsequ
sheep
underw
phlebotomi
period
interv
among
sheep
receiv
blood
iatrogen
infect
donor
sheep
given
blood
donor
preclin
bse
phase
develop
bse
receiv
blood
clinic
affect
sheep
show
clinic
sign
bse
among
sheep
transfus
blood
natur
scrapieinfect
anim
demonstr
clinic
sign
scrapi
activ
investig
determin
whether
transfus
associatedvcjd
transmiss
occur
human
began
unit
kingdom
identifi
vcjd
patient
donat
blood
ill
eventu
recipi
blood
donor
vcjd
identifi
three
recipi
date
evid
vcjd
one
age
year
receiv
nonleukocytereduc
rbc
donor
develop
vcjd
year
blood
donat
transfus
recipi
develop
vcjd
year
transfus
second
patient
receiv
transfus
nonleukocytereduc
rbc
donor
develop
vcjd
month
later
asymptomat
recipi
die
ruptur
abdomin
aortic
aneurysm
year
transfus
autopsi
proteaseresist
prion
present
spleen
cervic
lymph
node
prion
detect
brain
recipi
found
heterozyg
methioninevalin
codon
clinic
vcjd
rais
concern
incub
period
may
longer
codon
heterozygot
anim
studi
primari
challeng
vcjd
prion
result
significantli
reduc
transmiss
rate
mice
valin
codon
compar
anim
homozyg
methionin
addit
data
need
confirm
whether
incub
period
vari
among
methionin
homozyg
heterozyg
individu
third
case
develop
vcjd
approxim
year
receiv
nonleukocytereduc
red
cell
person
develop
vcjd
month
postdon
uk
nation
blood
servic
also
determin
approxim
peopl
donat
blood
four
patient
subsequ
show
clinic
sign
vcjd
donor
notifi
may
higher
risk
develop
vcjd
despit
uncertainti
whether
patient
contract
vcjd
food
blood
transfus
addit
uk
author
notifi
recipi
factor
xi
concentr
donor
compon
develop
vcjd
donat
ethic
tenet
transpar
unit
kingdom
current
import
plasma
unit
state
patient
younger
year
use
apheresisderiv
platelet
patient
reduc
donor
exposur
identif
presum
transfusionassoci
vcjd
case
appear
valid
step
taken
respons
precautionari
principl
decreas
risk
transmit
vcjd
transfus
donor
visit
resid
unit
kingdom
cumul
period
month
longer
defer
indefinit
donor
spent
year
europ
present
also
defer
addit
donor
indefinit
defer
inject
bovin
insulin
receiv
transfus
unit
kingdom
franc
present
serv
militari
base
europ
month
geographybas
donordeferr
protocol
evolv
variou
phase
begin
approxim
potenti
donor
unit
state
defer
result
polici
impact
higher
canada
indat
blood
compon
plasma
intend
deriv
product
donor
must
recal
quarantin
destroy
ongo
surveil
vcjd
case
increas
identif
texa
cow
bse
current
conduct
includ
recommend
notifi
cdc
patient
younger
year
diagnos
cjd
addit
geograph
exclus
polici
strategi
prevent
vcjd
transmiss
includ
remov
infecti
agent
test
unit
kingdom
blood
compon
undergo
leukocyt
reduct
filtrat
base
observ
prion
associ
leukocyt
leukocyt
reduct
howev
partial
effect
remov
total
prion
infect
filter
specif
remov
prion
laboratori
test
detect
infecti
prion
current
develop
evalu
latter
implement
accompani
signific
ethic
concern
viscer
form
leishmaniasi
result
infect
leishmania
donovani
leishmania
infantum
cutan
lesion
occur
person
infect
leishmania
braziliensi
leishmania
tropica
caus
old
world
cutan
leishmaniasi
howev
least
eight
soldier
return
eastern
saudi
arabia
oper
desert
storm
develop
viscer
leishmaniasi
attribut
l
tropica
leishmania
organ
transmit
primarili
bite
infect
sand
fli
endem
tropic
subtrop
region
sudan
eastern
india
bangladesh
nepal
brazil
mediterranean
transmiss
sand
fli
bite
parasit
resid
intracellularli
monocyt
circul
take
resid
intern
organ
sever
manifest
viscer
leishmaniasi
kalaazar
patient
mark
hepatosplenomegali
pancytopenia
hypergammaglobulinemia
cachexia
incub
period
approxim
month
antil
donovani
antibodi
form
shortli
infect
studi
conduct
brazil
seroposit
asymptomat
blood
donor
found
posit
pcr
result
l
donovani
demonstr
ongo
potenti
transfus
transmiss
endem
area
least
transfusionassoci
case
leishmaniasi
attribut
l
donovani
report
endem
region
infect
young
children
neonat
probabl
case
platelet
transfusiontransmit
leishmania
report
recent
transfusiontransmiss
also
appear
occur
dog
receiv
transfus
rbc
seroposit
dogblood
donor
veteran
oper
desert
storm
serv
persian
gulf
region
august
decemb
defer
blood
donat
year
report
l
tropicarel
viscerotrop
leishmaniasi
patient
nonspecif
clinic
manifest
includ
prolong
fever
malais
abdomin
pain
intermitt
diarrhea
occur
month
return
unit
state
l
tropica
found
bone
marrow
seven
patient
lymph
node
one
patient
intracellular
amastigot
seen
peripher
blood
one
patient
studi
report
hundr
case
cutan
leishmaniasi
two
case
viscer
leishmaniasi
troop
involv
iraq
war
similar
deferr
departur
iraq
institut
octob
l
tropica
within
human
monocyt
surviv
blood
store
c
c
frozen
rbc
platelet
concentr
store
room
temperatur
howev
l
tropica
detect
rel
cellfre
fresh
frozen
plasma
anim
studi
demonstr
transmiss
contamin
blood
case
transfusiontransmit
leishmaniasi
report
unit
state
date
reason
surveil
target
donor
deferr
appear
appropri
use
leukocyt
filter
reduc
leishmania
transmiss
investig
toxoplasma
gondii
ubiquit
parasit
whose
usual
host
domest
cat
infect
sometim
result
lymphadenopathi
malais
fever
headach
sore
throat
splenomegali
hepatomegali
rash
retinopathi
lethal
infect
occur
immunocompromis
host
transfus
transmiss
report
howev
case
occur
among
leukemia
patient
given
granulocyt
transfus
obtain
leukem
patient
anoth
case
report
suggest
patient
undergo
chemotherapi
leukem
relaps
year
receiv
allogen
marrow
transplant
develop
toxoplasma
pneumon
person
serolog
evid
recent
toxoplasma
infect
donat
one
unit
blood
transfus
patient
addit
woman
druginduc
thrombocytopenia
develop
toxoplasma
retinochoroid
presum
relat
platelet
transfus
case
emphas
import
nontradit
rout
infect
immunocompromis
patient
involv
renal
transplant
recipi
develop
toxoplasmosi
infect
presum
transmit
kidney
obtain
seroposit
organ
donor
dengu
transmit
aed
mosquito
infect
least
us
travel
caribbean
island
includ
puerto
rico
us
virgin
island
pacif
island
asia
central
america
africa
hawaii
incub
period
day
infect
caus
either
symptom
mild
ill
sever
diseas
includ
hemorrhag
manifest
shock
transmiss
bone
marrow
transplant
sever
report
transmiss
needlestick
injuri
involv
symptomat
patient
rais
possibl
transfus
transmiss
asymptomat
travel
return
endem
area
nonhuman
primat
zoo
anim
research
facil
infect
simian
foami
viru
sfv
endogen
cellassoci
retroviru
found
new
old
world
primat
surveil
studi
indic
approxim
zoo
biomed
research
personnel
work
chimpanze
baboon
infect
sfv
evalu
archiv
sampl
document
infect
year
median
year
subject
remain
healthi
three
spous
undergo
test
sfv
nonreact
addit
bush
hunter
central
africa
expos
freerang
nonhuman
primat
asia
test
posit
sfv
presum
infect
inocul
exposur
saliva
bite
close
contact
exposur
bodi
fluid
limit
inform
avail
transfus
transmiss
one
occup
expos
sfvinfect
individu
donat
blood
time
interv
sfv
test
result
conduct
retrospect
posit
none
test
recipi
rbc
leukocytereduc
rbc
platelet
sfv
posit
three
blood
compon
store
less
day
infect
lymphocyt
choriomenig
viru
lcmv
rodentborn
arenaviru
usual
caus
mild
selflimit
ill
asept
mening
nonimmunosuppress
patient
human
infect
typic
follow
exposur
bodi
fluid
infect
anim
excret
vertic
transmiss
occur
lcmv
consid
communic
person
person
lcmv
transmit
four
organ
transplant
recipi
via
asymptomat
organ
donor
cerebrovascular
accid
subsequ
brain
death
donor
appar
becam
infect
exposur
pet
hamster
within
week
transplant
recipi
liver
lung
two
kidney
develop
fever
rash
diarrhea
three
four
recipi
die
previou
case
also
involv
four
transplant
recipi
unrecogn
case
report
transfus
transmiss
report
possibl
given
transmiss
solidorgan
transplant
avian
influenza
viru
spread
epidem
among
bird
poultri
sinc
emerg
hong
kong
sinc
time
million
bird
poultri
die
cull
prevent
epidem
progress
via
bird
migrat
cambodia
china
indonesia
japan
lao
south
korea
thailand
vietnam
malaysia
turkey
romania
russia
transmiss
human
via
contact
infect
poultri
contamin
surfac
result
death
date
humantohuman
transmiss
occur
infrequ
howev
concern
exist
mutat
reassort
recombin
rearrang
viru
pathogen
human
influenza
virus
could
produc
viru
capabl
jump
speci
barrier
caus
worldwid
pandem
influenza
viremia
infrequ
although
highli
pathogen
avian
influenza
transmit
via
blood
although
transfus
transmiss
theoret
risk
like
impact
would
largescal
donor
ill
blood
shortag
sar
caus
novel
envelop
rna
coronaviru
infect
patient
countri
februari
march
highli
contagi
ill
domin
worldwid
public
health
attent
result
rapid
identif
travel
advisori
patient
quarantin
eventu
erad
epidem
asymptomat
incub
period
foster
spread
viru
close
persontoperson
contact
rais
possibl
bloodborn
infect
reason
us
fda
issu
guidanc
document
april
requir
bloodcollect
agenc
defer
anyon
donat
blood
least
day
possibl
exposur
sar
suspect
sar
ill
defer
least
day
recoveri
notic
post
blood
center
appris
donor
sarsaffect
area
donor
ask
recent
travel
histori
travel
affect
area
includ
transit
airport
locat
defer
blood
donat
epidem
subsid
within
month
report
transfusionassoci
sar
exist
west
nile
viru
wnv
mosquitoborn
lipidenvelop
rna
viru
japanes
enceph
flavirida
complex
viral
genom
code
capsid
membran
envelop
nonstructur
protein
viru
transmit
bird
bird
mosquito
vector
infect
human
incident
host
viru
identifi
west
nile
district
uganda
outbreak
occur
subsequ
mideast
south
africa
europ
first
north
american
case
record
new
york
citi
addit
virem
blood
donor
identifi
wnv
activ
bird
mosquito
occur
throughout
year
especi
warmer
region
viru
becom
detect
blood
day
mosquito
bite
follow
increas
viral
load
howev
peak
titer
rel
low
median
copi
per
millilit
compar
hiv
hcv
per
millilit
rna
level
decreas
markedli
day
infect
immunoglobulin
igm
antibodi
subsequ
igg
anitibodi
appear
igm
antibodi
persist
day
approxim
two
third
infect
mean
durat
viremia
day
howev
wnv
rna
detect
day
infect
one
blood
donor
approxim
person
infect
wnv
remain
asymptomat
symptomat
infect
report
abdomin
pain
chill
fever
gener
weak
headach
joint
pain
muscl
weak
pain
new
macular
rash
trunk
extrem
new
difficulti
think
pain
eye
swollen
gland
one
infect
person
develop
mening
enceph
asymmetr
flaccid
paralysi
fatal
outcom
occur
sever
diseas
wnv
transmiss
four
recipi
organ
donat
report
organ
donor
turn
receiv
blood
transfus
donor
one
subsequ
found
wnv
infect
sampl
organ
donor
subsequ
test
wnv
rna
posit
wnv
igm
neg
initi
report
transmiss
blood
transfus
eventu
result
confirm
case
transfusionassoci
wnv
infect
interv
transfus
symptom
onset
day
median
interv
rang
day
nine
implic
blood
donor
report
wnvassoci
symptom
donat
intens
collabor
among
us
public
health
author
test
manufactur
bloodcollect
agenc
nat
wnv
rna
implement
wnv
season
direct
result
test
donor
found
wnv
rna
posit
prevent
wnv
transmiss
approxim
recipi
rbc
compon
prepar
donat
summer
month
approxim
per
unit
wnv
rna
posit
high
wnv
endem
area
approxim
donor
wnv
virem
six
transfusionassoci
wnv
case
report
implic
donor
extrem
lowlevel
viremia
escap
detect
routin
test
minipool
contain
aliquot
donat
test
individu
sampl
highincid
area
increas
test
sensit
approxim
introduc
incid
case
exceed
preestablish
threshold
approxim
wnvposit
donor
per
donat
one
confirm
transmiss
occur
among
confirm
transfus
case
implic
donat
wnv
igm
antibodi
neg
second
transplantassoci
incid
involv
three
four
organ
recipi
develop
wnv
infect
transplant
report
note
organ
donor
infect
mosquito
bite
wnv
rna
posit
igm
antibodi
posit
report
rais
concern
organtranspl
recipi
heavili
immunosuppress
patient
extrem
high
risk
sever
wnv
complic
viru
remain
viabl
organ
tissu
reservoir
despit
humor
immun
respons
overal
rapid
implement
wnv
test
within
month
initi
transplant
transfusionassoci
case
result
dramat
reduct
transfusiontransmit
case
assum
rnaposit
igm
antibodyposit
donor
transmit
wnv
blood
transfus
residu
risk
transfusionassoci
wnv
implement
nat
approxim
per
donat
june
cdc
confirm
diagnosi
rabi
recipi
liver
two
kidney
organ
donor
subsequ
found
infect
rabi
via
bat
bite
recipi
develop
tremor
myoclon
jerk
alter
mental
statu
anorexia
day
transplant
die
unlik
transplantrel
case
portend
risk
transfusiontransmiss
exposur
infect
neuron
tissu
appear
vector
case
rabi
viru
transmit
hematolog
contact
blood
urin
fece
consid
exposur
risk
day
post
infecti
mosquito
bite
wnv
rna
geq
per
ml
